ISOPRENOIDS IN AGING AND NEURODEGENERATION
ISOPRENOIDS IN AGING AND NEURODEGENERATION
复制标题
DOI：
10.1016/0197-0186(94)90050-7
复制
发表时间：
1994-07-01
影响因子：
4.2
通讯作者：
KRISTENSSON, K
中科院分区：
文献类型：
--
作者：
EDLUND, C;SODERBERG, M;KRISTENSSON, K
在衰老过程中，人脑显示出多萜醇水平的逐渐增加，泛醌水平的减少，但胆固醇和多萜醇磷酸盐的浓度相对不变。在神经退行性疾病，阿尔茨海默病，情况是逆转与降低水平的多萜醇和增加水平的泛醌。磷酸长酯的浓度也增加，而胆固醇保持不变。这项研究表明，阿尔茨海默病中的类异戊二烯变化不同于正常衰老过程中发生的变化，因此，这种疾病不能被认为是过早衰老的结果。糖载体磷酸长链甘油酯的增加可能反映了患病脑中糖基化速率的增加和内源性抗氧化剂泛醌的增加，试图保护脑免受氧化应激，例如由脂质过氧化诱导的氧化应激。
During aging the human brain shows a progressive increase in levels of dolichol, a reduction in levels of ubiquinone, but relatively unchanged concentrations of cholesterol and dolichyl phosphate. In a neurodegenerative disease, Alzheimer's disease, the situation is reversed with decreased levels of dolichol and increased levels of ubiquinone. The concentrations of dolichyl phosphate are also increased, while cholesterol remains unchanged. This study shows that the isoprenoid changes in Alzheimer's disease differ from those occuring during normal aging and that this disease cannot, therefore, he regarded as a result of premature aging. The increase in the sugar carrier dolichyl phosphate may reflect an increased rate of glycosylation in the diseased brain and the increase in the endogenous anti-oxidant ubiquinone an attempt to protect the brain from oxidative stress, for instance induced by lipid peroxidation.